VWValerie Williams

Valerie Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valerie Williams has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of anchor-based methods for estimating thresholds of meaningful within-patient change using simulated PROMIS PF 20a data under various joint distribution characteristic conditions

    by Shanshan Qin, Lauren Nelson, Nicole Williams, Valerie Williams, Randall Bender, Lori McLeod

    Purpose To compare the performance of anchor-based methods for estimating thresholds of meaningful within-patient change (i.e., individual change) of clinical outcome assessments in conditions reflecting data characteristics of small- to medium-sized clinical trials. Methods Datasets were generated from the joint distributions of the PROMIS PF 20a T-score changes and a seven-point global change anchor measure. The 108 simulation conditions (1000 replications per condition) included combinations of three marginal distributions of T-score changes, three improvement percentages in the anchor measure, four levels of responsiveness correlations, and three sample sizes. Threshold estimation methods included mean change, median change, ROC curve, predictive modeling, half SD, and SEM. Relative bias, precision, accuracy, and measurement significance of the estimates were evaluated based on comparison with true thresholds and IRT-based individual reliable changes of PROMIS scores. Quantile regression models were applied to select and interpret effects of simulation conditions on estimation bias. Results When PROMIS T-score changes were distributed normally, the predictive modeling method performed best with 50% or more responders identified by the anchor; the mean and median methods were preferred with 30% responders. For skewed distributions, the median method and ROC method gained more advantages. Among the evaluated study conditions, the improvement percentage condition had the most obvious effects on estimation bias. Conclusion To establish accurate and precise thresholds, clinical researchers are recommended to prioritize study designs with at least 50% anchor-defined responders and strongly responsive target endpoints with highly reliable scoring calibration and to select optimal anchor-based methods given the data characteristics.


  • Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis

    by Anthony A. Amato, Michael G. Hanna, Pedro M. Machado, Umesh A. Badrising, Hector Chinoy, Olivier Benveniste, Ananda Krishna Karanam, Min Wu, László B. Tankó, Agnes Annette Schubert-Tennigkeit, et al.

    Objective To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). Methods Participants (aged 36–85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients]) were invited to join an extension study. Individuals continued on the same treatment as in the core study (10 mg/kg, 3 mg/kg, 1 mg/kg bimagrumab or matching placebo administered as IV infusions every 4 weeks). The co–primary outcome measures were 6-minute walk distance (6MWD) and safety. Results Between November 2015 and February 2017, 211 participants entered double-blind placebo-controlled period of the extension study. Mean change in 6MWD from baseline was highly variable across treatment groups, but indicated progressive deterioration from weeks 24–104 in all treatment groups. Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had ≥1 treatment-emergent adverse event (AE). Falls were slightly higher in the bimagrumab 3 mg/kg group vs 10 mg/kg, 1 mg/kg, and placebo groups (69.2% [n = 36 of 52] vs 56.6% [n = 30 of 53], 58.8% [n = 30 of 51], and 61.8% [n = 34 of 55], respectively). The most frequently reported AEs in the pooled bimagrumab group were diarrhea 14.7% (n = 23), involuntary muscle contractions 9.6% (n = 15), and rash 5.1% (n = 8). Incidence of serious AEs was comparable between the pooled bimagrumab and the placebo group (18.6% [n = 29] vs 14.5% [n = 8], respectively). Conclusion Extended treatment with bimagrumab up to 2 years produced a good safety profile and was well-tolerated, but did not provide clinical benefits in terms of improvement in mobility. The extension study was terminated early due to core study not meeting its primary endpoint. Clinical Trial Registration Clinicaltrials.gov identifier NCT02573467. Classification of Evidence This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2.


  • Home-based physical activity interventions for breast cancer patients receiving primary therapy: a systematic review

    by Steven S. Coughlin, Lee S. Caplan, Valerie Williams

    Breast cancer continues to be the leading cause of cancer in women in the US, so it is important to provide these women with good therapies. However, there are adverse effects to these therapies. Physical activity plays an important role in alleviating these adverse effects of breast cancer therapy. However, the effectiveness of home-based physical activity interventions such as walking programs has not been detailed by prior reviews.


  • Validation of the Sporadic Inclusion Body Myositis Physical Functioning Assessment (P3.122)

    by Valerie Williams, Theresa Coles, Carla Demuro, Sandra Lewis, Nicole Williams, Stuart Yarr, Victoria Barghout, Linda Lowes, Lindsay Alfano, Bob Goldberg, et al.

  • Open Access

    Enriching Education with Exemplars in Practice: Iterative Development of Data Curation Internships

    by Matthew S. Mayernik, Cheryl A. Thompson, Valerie Williams, Suzie Allard, Carole L. Palmer, Carol Tenopir

    Partnerships between educational programs and research centers are vital to meeting the escalating workforce demands in data curation. They offer a platform for educators to increase their knowledge of current best practices and emerging challenges in the field. Student internships can be key to the success of these partnerships, not just for the students who gain authentic experience in facilities that excel at data intensive research and data services. Such partnerships provide an effective platform for rich and mutually beneficial engagement among educators, data professionals, scientists, and students. This paper reports on results from the Data Curation Education in Research Centers (DCERC) program aimed at developing a model for data curation education featuring field experiences in exemplar research centers. A strength of the DCERC model is its emphasis on facilitating mutual exchange of information among the DCERC program mentors and students. This model has evolved as a result of iterative and gradual refinements to the program model based upon information gathered from the formative evaluation. These refinements not only resulted in improved outcomes for the program participants but also, we believe, a more sustainable model for the program that leverages the knowledge base of the research scientists and students through peer-to-peer learning, rather than a traditional expert to trainee model. This paper describes formative evaluation findings that shaped the development of the DCERC program. We conclude with a discussion of the critical features of this model for the development of similar programs, and a data curation workforce that is able to accommodate and adapt to emergent data needs in a variety of environments.


  • Open Access

    Psychometric validation of patient-reported outcome measures assessing chronic constipation

    by Valerie Sl Williams, Sheri Fehnel, Robyn T Carson, James MacDougall, Mollie J Baird, Stavros Tourkodimitris, Caroline B Kurtz, Jeffrey M Johnston, Lauren M Nelson

    Background: Measures assessing treatment outcomes in previous CC clinical trials have not met the requirements described in the US Food and Drug Administration's guidance on patient-reported outcomes. Aim: Psychometric analyses using data from one Phase IIb study and two Phase III trials of linaclotide for the treatment of chronic constipation (CC) were conducted to document the measurement properties of patient-reported CC Symptom Severity Measures. Study methods: Each study had a multicenter, randomized, double-blind, placebo-controlled, parallel-group design, comparing placebo to four doses of oral linaclotide taken once daily for 4 weeks in the Phase IIb dose-ranging study (n=307) and to two doses of linaclotide taken once daily for 12 weeks in the Phase III trials (n=1,272). The CC Symptom Severity Measures addressing bowel function (Bowel Movement Frequency, Stool Consistency, Straining) and abdominal symptoms (Bloating, Abdominal Discomfort, Abdominal Pain) were administered daily using interactive voice-response system technology. Intraclass correlations, Pearson correlations, factor analyses, F-tests, and effect sizes were computed. Results: The CC Symptom Severity Measures demonstrated satisfactory test–retest reliability and construct validity. Factor analyses indicated one factor for abdominal symptoms and another for bowel symptoms. Known-groups F-tests substantiated the discriminating ability of the CC Symptom Severity Measures. Responsiveness statistics were moderate to strong, indicating that these measures are capable of detecting change. Conclusion: In large studies of CC patients, linaclotide significantly improved abdominal and bowel symptoms. These psychometric analyses support the reliability, validity, discriminating ability, and responsiveness of the CC Symptom Severity Measures for evaluating treatment outcomes in the linaclotide clinical studies.


  • An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trials

    by J. E. MacDougall, J. M. Johnston, B. J. Lavins, L. M. Nelson, V. S. L. Williams, R. T. Carson, S. J. Shiff, K. Shi, C. B. Kurtz, M. J. Baird, et al.

    Background: Our objective was to evaluate the performance of the Food and Drug Administration (FDA) Responder Endpoint for clinical trials in IBS‐C, using data from two large Phase 3 clinical trials of linaclotide. The FDA interim endpoint requires that, for 50% of trial weeks, patients report ≥30% decrease in Abdominal Pain at its worst and (in the same week) an increase in Complete Spontaneous Bowel Movements (CSBMs) of ≥1 from baseline.Methods: Anchor‐based methodology was used to estimate thresholds of clinically meaningful change using symptom‐specific patient rating of change questions (PRCQs) and symptom severity questions. The diagnostic accuracy of the FDA Responder Endpoint was assessed using sensitivity/specificity‐based methods.Key Results: Using anchor‐based methods, the estimates of the clinically meaningful improvement thresholds for Abdominal Pain ranged from 25.9% to 32.4% and thresholds for increase in weekly CSBM rate ranged from 1.4 to 1.6 CSBMs per week. Compared with the symptom‐specific PRCQs for patient rating of relief, the FDA Responder Endpoint has a sensitivity of 60.7%, a specificity of 93.5%, and an accuracy of 82.0%. Changing the number of weeks required to be a responder or the percentage improvement in the Abdominal Pain criteria did not result in notable improvement in the accuracy of the FDA Responder Endpoint.Conclusions & Inferences: The FDA Responder Endpoint for IBS‐C clinical trials represents clinically meaningful improvements in IBS‐C symptoms for patients with excellent specificity and reasonable sensitivity.


  • Open Access

    Elementary School–Located Influenza Vaccine Programs

    by Valerie Williams, Matthew D. Rousculp, Mark Price, Theresa Coles, Michelle Therrien, Jane Griffin, Kelly Hollis, Seth Toback

    This study examined the initiation and logistics, funding, perceived barriers and benefits, and disruption of school activities by school-located influenza vaccination (SLIV) programs conducted during the 2008–2009 influenza season. Seventy-two interviews using a structured protocol were conducted with 26 teachers, 16 school administrators, and 30 health care professionals from 34 schools in 8 school districts. SLIV programs used a variety of locations, scheduling and staffing options, and methods for receiving parental consent and screening children. Health care professionals were primarily responsible for implementing SLIV programs, and most administrators and health care professionals considered programs easy to initiate. Health care professionals identified successful programs as requiring adequate planning/coordination, a dedicated program coordinator, and a consistent funding source. Most respondents (96%) reported minimal school-day disruptions. The perception of most stakeholders is that SLIV programs can be relatively easy to initiate, minimally disruptive and can become more efficient with experience, especially with feedback from all stakeholders.


  • Placebo Response Screening Scale

    by Douglas Feltner, Cheryl Hill, William Lenderking, Valerie Williams, Robert Morlock